2020 American Transplant Congress
Clinical and Laboratory Characteristics of Early and Late-Onset Cytomegalovirus Infection Following Universal Prophylaxis in Kidney Transplant Recipients
University of California, San Francisco, San Francisco, CA
*Purpose: Cytomegalovirus (CMV) is the most important viral infection in organ recipients and can cause life-threatening infections, compromising long-term graft function. Most transplant centers use…2020 American Transplant Congress
An OPO’s Experience in Increasing Transplantation with the Hope Project
*Purpose: The purpose of this report is to describe one OPO’s experience in participating in the Hope Project. This research project is designed to evaluate…2020 American Transplant Congress
Preemptive Direct Acting Antiviral Therapy as Prophylaxis in Donor HCV-Positive to Recipient HCV-Negative Solid Organ Transplant: a Comprehensive Review
Gastroenterology, Louisiana State University of Health Sciences Shreveport, Shreveport, LA
*Purpose: With the advent of highly effective and safe oral Direct acting Antiviral agents (DAAs), several transplant centers have adopted protocols for using HCV positive…2020 American Transplant Congress
Cytomegalovirus Infection and Outcomes in Pancreas Transplant Recipients in the Prophylaxis Era
1UW Health, Madison, WI, 2UWMF, Madison, WI
*Purpose: Evaluate epidemiology and outcomes of cytomegalovirus infection (CMV) in pancreas transplant recipients (PTR) in the current era of valganciclovir (VGC) prophylaxis (PPX)*Methods: Adult PTRs…2020 American Transplant Congress
Comparison of Prophylaxis Strategies for CMV Infection in Liver Transplant Recipients
The Ohio State Wexner Medical Center, Columbus, OH
*Purpose: The best strategy to prevent cytomegalovirus (CMV) following liver transplantation is not defined for intermediate risk recipients (recipient seropositive (R+) regardless of donor status).…2020 American Transplant Congress
Brincidofovir for Adenovirus Disease in Adult Renal Transplant Recipients: A Case Series
*Purpose: Adenovirus infection can lead to disease in solid organ transplant recipients, including disease of the allograft. Treatment options for severe disease are limited. Brincidofovir…2020 American Transplant Congress
Utilization of Organs from Donors Exposed to Hepatitis C: ? Standard of Care
*Purpose: To report the results of a clinical program to utilize livers and kidneys from donors exposed to Hepatitis C.*Methods: We initially started to explore…2020 American Transplant Congress
Viral Kinetics of De Novo HCV Infection and Response to Antiviral Therapy in Liver and Kidney Transplant Recipients Receiving HCV-Viremic Donors
*Purpose: There is general agreement that expanded use of organs from HCV-viremic donors is desirable, including in recipients without HCV infection. However, the optimal treatment…2020 American Transplant Congress
Efficacy of Generic Sofosbuvir and Branded Daclatasvir Compared to Sofosbuvir and Ledipasvir Combination in the Treatment of Genotype 4 Hepatitis C Virus
King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
*Purpose: Genotype 4 HCV is the most common genotype in Saudi Arabia and the Middle East. Management of HCV has shifted in the last few…2020 American Transplant Congress
Glecaprevir-Pibrentasvir Effect on Tacrolimus Troughs in Abdominal Transplant Recipients
The Ohio State Wexner Medical Center, Columbus, OH
*Purpose: Glecaprevir-pibrentasvir (GP) is one of several pangenotypic therapies available for the treatment of hepatitis C. Historical use of ritonavir based hepatitis C therapies increased…
American Transplant Congress abstracts